Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jul 6;14(14):2789.
doi: 10.3390/nu14142789.

Metagenomic Changes of Gut Microbiota following Treatment of Helicobacter pylori Infection with a Simplified Low-Dose Quadruple Therapy with Bismuth or Lactobacillus reuteri

Maria Pina Dore  1 , Rosangela Sau  2 , Caterina Niolu  1 , Marcello Abbondio  2 , Alessandro Tanca  2 , Stefano Bibbò  3 , Mariafrancesca Loria  1 , Giovanni Mario Pes  1 , Sergio Uzzau  2
Affiliations
Randomized Controlled Trial

Metagenomic Changes of Gut Microbiota following Treatment of Helicobacter pylori Infection with a Simplified Low-Dose Quadruple Therapy with Bismuth or Lactobacillus reuteri

Maria Pina Dore et al. Nutrients. .

Abstract

Background: Probiotic supplementation to antibiotic regimens against Helicobacter pylori infection has been proposed to improve eradication rate and to decrease detrimental effects on gut microbiota.

Aims: To evaluate microbiota modifications due to a low-dose quadruple therapy with bismuth or Lactobacillus reuteri.

Methods: Forty-six patients infected with H. pylori were prospectively enrolled in a single-centre, randomized controlled trial to receive b.i.d. with meals for 10 days low-dose quadruple therapy consisting of rabeprazole 20 mg and bismuth (two capsules of Pylera® plus 250 mg each of tetracycline and metronidazole), or the same dose of rabeprazole and antibiotics plus Gastrus® (L. reuteri), one tablet twice-a-day for 27 days. Stool samples were collected at the enrolment, at the end and 30-40 days after the treatment. Gut microbiota composition was investigated with 16S rRNA gene sequencing.

Results: Eradication rate was by ITT 78% in both groups, and by PP analysis 85.7% and 95.5% for Gastrus® and bismuth group, respectively. Alpha and beta diversity decreased at the end of treatment and was associated with a reduction of bacterial genera beneficial for gut homeostasis, which was rescued 30-40 days later in both groups, suggesting a similar impact of the two regimens in challenging bacterial community complexity.

Conclusions: Low-dose bismuth quadruple therapy proved to be effective with lower costs and amount of antibiotics and bismuth. Gastrus® might be an option for patients with contraindications to bismuth. L. reuteri was unable to significantly counteract dysbiosis induced by antibiotics. How to administer probiotics to prevent gut microbiota alterations remains an open question.

Keywords: 16S rRNA gene sequencing; human gut microbiota; probiotics; randomized clinical trial.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Study design of the controlled trial. The symbols * and § represent the treatment according to the Table 1.
See this image and copyright information in PMC

References

    1. Kikuchi S., Dore M.P. Epidemiology of Helicobacter pylori Infection. Helicobacter. 2005;10((Suppl. S1)):1–4. doi: 10.1111/j.1523-5378.2005.00335.x. - DOI - PubMed
    1. Wu J.Y., Lee Y.C., Graham D.Y. The eradication of Helicobacter pylori to prevent gastric cancer: A critical appraisal. Expert Rev. Gastroenterol. Hepatol. 2019;13:17–24. doi: 10.1080/17474124.2019.1542299. - DOI - PMC - PubMed
    1. Lee Y.C., Dore M.P., Graham D.Y. Diagnosis and Treatment of Helicobacter pylori Infection. Annu. Rev. Med. 2022;73:183–195. doi: 10.1146/annurev-med-042220-020814. - DOI - PubMed
    1. Dore M.P., Marras L., Maragkoudakis E., Nieddu S., Manca A., Graham D.Y., Realdi G. Salvage therapy after two or more prior Helicobacter pylori treatment failures: The super salvage regimen. Helicobacter. 2003;8:307–309. doi: 10.1046/j.1523-5378.2003.00150.x. - DOI - PubMed
    1. Shiotani A., Lu H., Dore M.P., Graham D.Y. Treating Helicobacter pylori effectively while minimizing misuse of antibiotics. Cleve Clin. J. Med. 2017;84:310–318. doi: 10.3949/ccjm.84a.14110. - DOI - PMC - PubMed

Publication types

MeSH terms